A study of datopotamab deruxtecan with or without durvalumab for triple negative breast cancer that has spread or come back (TROPION-Breast05)

Overview

Cancer types:

Breast cancer, Secondary cancers

Status:

Open

Phase:

Phase 3

Details

This study is looking at datopotamab deruxtecan with or without durvalumab. You pronounce datopotamab deruxtecan as dat-oh-pot-oh-mab deh-rux-tee-can. It is comparing it to standard chemotherapy with immunotherapy for triple negative breast cancer.

It is for people with breast cancer cells that have a high level of protein called PD-L1. And the cancer has either:

spread from where it started to other parts of the body (metastatic breast cancer)
come back in the area where it started after treatment (local recurrence) and cannot be fully removed with surgery